$4.5 million investment into cancer vaccine

Malaghan Institute
Scoop Independent News
06/10/2010

$4.5 million investment into development of cancer vaccine

Treating cancer patients with a vaccine is one step closer to reality as a result of $4.5 million investment of Health Research Council of New Zealand funding in cancer research.

Dr Ian Hermans, who heads the HRC-funded cancer vaccine research programme at the Malaghan Institute of Medical Research, based at Victoria University of Wellington’s Kelburn campus, says the funded study has developed from more than a decade’s worth of research into developing techniques that train a patient’s immune system to fight their cancer.

While the research will focus specifically on targeting melanoma, it is anticipated that the methodology being developed could be applied to other cancers in the future.

The therapeutic vaccine approach differs from the preventative vaccines used to protect against diseases such as measles or the flu because the cancer vaccine is designed to be given to an individual after they have already shown signs of disease.

Read the rest of the article.

About the author

VT

Jeffry John Aufderheide is the father of a child injured as a result of vaccination. As editor of the website www.vactruth.com he promotes well-educated pediatricians, informed consent, and full disclosure and accountability of adverse reactions to vaccines.